Subsequent investigations in TALL-1 cells indicated that biological effects associated to GSKJ4 and A-485 might be mostly due to the inhibition of the Notch/c-Myc regulatory axis, as both treatments converged to c-Myc suppression and its enforced expression preserved cells from the treatment-associated effects on T-ALL cell viability. The gene discussed is MYC; the disease is acute lymphoblastic leukemia.